The Journal of Urology
Volume 182, Issue 3 , Pages 900-906 , September 2009

Adjuvant Chemotherapy for High Risk Upper Tract Urothelial Carcinoma: Results From the Upper Tract Urothelial Carcinoma Collaboration

  • Nicholas J. Hellenthal

      Affiliations

    • University of California-Davis, Sacramento, California
    • Corresponding Author InformationCorrespondence: Department of Urology, 4860 Y St., Suite 3500, University of California-Davis Medical Center, Sacramento, California 95817 (telephone: 916-734-2893; FAX: 916-734-8094)
    • ,
  • Shahrokh F. Shariat

      Affiliations

    • University of Texas Southwestern, Dallas, Texas
    • ,
  • Vitaly Margulis

      Affiliations

    • University of Texas M. D. Anderson Cancer Center, Houston, Texas
    • ,
  • Pierre I. Karakiewicz

      Affiliations

    • University of Montreal, Montreal, Quebec, Canada
    • ,
  • Marco Roscigno

      Affiliations

    • University of Vienna, Vienna, Austria
    • ,
  • Christian Bolenz

      Affiliations

    • University of Texas Southwestern, Dallas, Texas
    • Universitatsklinikum Mannheim, Mannheim, Germany
    • ,
  • Mesut Remzi

      Affiliations

    • Vita-Salute University, Milan, Italy
    • ,
  • Alon Weizer

      Affiliations

    • University of Michigan, Ann Arbor, Michigan
    • ,
  • Richard Zigeuner

      Affiliations

    • Medical University Graz, Graz, Austria
    • ,
  • Karim Bensalah

      Affiliations

    • University of Rennes, Rennes, France
    • ,
  • Casey K. Ng

      Affiliations

    • Cornell University, New York, New York
    • ,
  • Jay D. Raman

      Affiliations

    • Cornell University, New York, New York
    • ,
  • Eiji Kikuchi

      Affiliations

    • Keio University School of Medicine, Tokyo, Japan
    • ,
  • Francesco Montorsi

      Affiliations

    • Vita-Salute University, Milan, Italy
    • ,
  • Mototsugu Oya

      Affiliations

    • Keio University School of Medicine, Tokyo, Japan
    • ,
  • Christopher G. Wood

      Affiliations

    • University of Texas M. D. Anderson Cancer Center, Houston, Texas
    • Financial interest and/or other relationship with Antigenics, Pfizer, Bayer/Onyx, Kidney Cancer Association and Ethicon.
    • ,
  • Mario Fernandez

      Affiliations

    • Clinica Alemana de Santiago, Santiago de Chile, Chile
    • ,
  • Christopher P. Evans

      Affiliations

    • University of California-Davis, Sacramento, California
    • ,
  • Theresa M. Koppie

      Affiliations

    • University of California-Davis, Sacramento, California

Received 16 December 2008

  • Image Result

    Overall (OS) and cancer specific (CSS) survival in patients with high risk UTUC with (red curves) vs without (blue curves) adjuvant chemotherapy.

    Overall (OS) and cancer specific (CSS) survival in patients with high risk UTUC with (red curves) vs without (blue curves) adjuvant chemotherapy.

  • Image Result

    Overall (OS) and cancer specific (CS) survival substratified by stage in patients with high risk UTUC with (red curves) vs without (blue curves) adjuvant chemotherapy.

    Overall (OS) and cancer specific (CS) survival substratified by stage in patients with high risk UTUC with (red curves) vs without (blue curves) adjuvant chemotherapy.

 Study received institutional review board approval.

PII: S0022-5347(09)01151-3

doi: 10.1016/j.juro.2009.05.011

The Journal of Urology
Volume 182, Issue 3 , Pages 900-906 , September 2009

Article Tools

* Image Usage & Resolution